Pathology Division revenue in June reached its breakeven point, and the company anticipates continued growth in the next few months. We expect this division's revenues will reach more than $1.5 million per month by year end, well above its breakeven goals. About Precipio Forward-Looking Statements NEW HAVEN, Conn., July 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that for Q2-2024, its unaudited revenues have grown from $3.4M in Q1- 2024 to $4.4M ...

no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws. Precipio shareholders as of the April 19, 2024 record date for the Annual Meeting are invited to attend the virtual Annual Meeting by visiting www.virtualshareholdermeeting.com/PRPO2024. About Precipio Forward-Looking Statements NEW HAVEN, Conn., June 13, 2024 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipi ...

During this process, we've realized that there are quite a few shareholders who didn't know whether their shares were voted on or not. You can accomplish this in one of three easy ways that will take no more than 60 seconds: The record date for determining shareholders eligible to vote at the Annual Meeting will remain the close of business on April 19, 2024. Shareholders who have already submitted a proxy do not need to vote again for the reconvened Annual Meeting, as the proxies submitted will remain vali ...

NEW HAVEN, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately today no later than 11pm Eastern Time. In order to ensure that there is a quorum required for the shareholders' meeting that is scheduled to take place tomorrow June 13, 2024 at 10 a.m. Eastern Time. At the time of this press release, approximately 44% of shares have been voted. For the com ...

In September of 2023, Precipio's pathology division exceeded its breakeven point of $15M annualized revenue run rate, resulting in a Q4 cash burn of less than $100K for the quarter. In the following quarter, as previously discussed, due to several operational issues, revenue declined below that point. 2. Change Healthcare hacking & cash impact This rule creates two options to comply: The FDA rule has stipulated that any tests that a lab was operating before the ruling on May 2023 are "grandfathered" into ap ...

WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents For the quarterly period ended March 31, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR (203) 787-7888 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-36439 PRECIPIO, INC. (Exact name of registrant as specified in its charter) Delawa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | Commission File Number: 001-36439 | | --- | PRECIPIO, INC. (Exact name of registrant as specified in its charter) Delaware 91-1789357 (State or other jurisdiction of incorpor ...

Financial Data and Key Metrics - Revenue grew by almost 30% quarter-over-quarter and doubled year-over-year, reaching $4.5 million in Q3 2023, putting the company on an annualized run rate of $18 million [8] - Cash burn dropped to around $1 million in Q3 2023, down approximately 40% from $2.5 million in the same quarter of the previous year [9] - The Pathology division reached a cash-neutral status, achieving a breakeven run rate of $14 million, while the Product division is on track to reach a reduced breakeven threshold of $6 million annually ($1.5 million per quarter) [13][15] Business Line Performance - Both the Pathology and Product businesses contributed to the revenue growth, with the Pathology division now operating as a cash-neutral entity [8][13] - The Product division has not yet reached its $8 million target but is expected to achieve a revised breakeven threshold of $6 million annually due to operational efficiencies [15] Market and Strategic Direction - The company's strategy focuses on developing and selling diagnostic products for laboratories, leveraging its cash-neutral Pathology division as a cost-free R&D center [18][19] - The release of the BCR-ABL assay in August 2023, developed at a cost of less than $100,000, exemplifies the company's low-cost product development model [20] - The total available market potential for products like HemeScreen is estimated at $400 million annually, with significant growth potential [23] Management Commentary on Operating Environment and Future Outlook - Management emphasized the importance of maintaining a frugal mindset even after achieving breakeven, highlighting operational efficiencies such as bringing billing functions in-house, which saves $50,000 to $75,000 monthly [14][17] - The company plans to focus on financial stability, product growth, and R&D development in 2024, including expanding the HemeScreen product line and developing new products [24][26] - Management intends to increase investor outreach through conferences, social media, and digital marketing campaigns to raise awareness of the company's financial success and growth potential [27] Other Key Information - The company believes it has sufficient cash reserves to achieve financial independence, even if it takes one or two more quarters to reach the target [16] - Investments in sales and marketing, as well as product production lines, are expected to yield positive ROI within 12 months, further improving business economics [21][22] Q&A Session - No specific questions or answers were provided in the transcript [30]

FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-36439 PRECIPIO, INC. (Exact name of registrant as specified in its charter) Delaware 91-17893 ...

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect. Question-and-Answer Session Q - Would we like to regain compliance organically? Of course, we would. But I also think that at the end of the day, as we continue to perform, this is - if this is a mathematical transaction, if it happens, not a value changing loan that may result in some of the benefits that our shareholders agree with us. Right now, our focus is on the aspects I've discussed today, increas ...